Loading…
Coherus Oncology, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -93.2% over 5Y.
today you would have $70.32▼ -93.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.42 | $1.38 | $3.33 | $7.92 | $15.96 | $17.38 | $18.00 | $9.05 | $8.80 | $28.15 | $22.96 | $16.32 | |
| P/E | 8.1x | 1.0x | 5.5x | — | — | — | 10.7x | 14.6x | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SPOKSpok Holdings, Inc | $10.40 | 18.2x | 1.6x | 12.02% | 8.42% | $217.55M |
| TARAProtara Therapeutics, Inc. | $3.68 | — | 1.3x | — | -45.80% | $217.47M |
| HITIHigh Tide Inc. | $2.51 | — | 3.5x | — | -37.90% | $220.55M |
| ALXOAlx Oncology Holdings Inc | $1.60 |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| P/S | 5.0x | 5.0x | 6.1x | 1.5x | 3.0x | 3.8x | 2.7x | 3.6x | — | 340.1x | 7.6x | 29.9x | 17.5x |
| P/B | 12.1x | 3.5x | — | — | — | 12.6x | 4.5x | 12.1x | — | 17.3x | 70.1x | — | 8.1x |
| EPS | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.62 | $1.23 | -$3.22 | -$4.48 | -$3.04 | -$6.01 | -$10.64 |
| Profit margin | -87.92% | 398.43% | 108.03% | -92.48% | -138.24% | -87.92% | 27.79% | 25.23% | — | -15306.56% | -66.98% | -743.18% | -280.12% |
| ROE | -130.44% | 275.39% | — | — | — | -293.78% | 47.07% | 85.38% | — | -779.99% | -620.34% | — | -130.44% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.6x |
| — |
| -80.65% |
| $221.24M |
| CNTNCanton Strategic Holdings, Inc. | $2.69 | — | 0.5x | — | -42.21% | $214.34M |
| NBPNovaBridge Biosciences | $1.84 | — | 1.1x | — | -59.10% | $212.79M |